SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
SEC Accession No. 0001213900-23-016044
Filing Date
2023-03-01
Accepted
2023-03-01 13:02:05
Documents
161

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM F-1 ea174488-f1a2_altamira.htm   iXBRL F-1/A 3632587
2 CONSENT OF DELOITTE AG ea174488ex23-1_altamira.htm EX-23.1 2273
8 GRAPHIC image_001.jpg GRAPHIC 3988
  Complete submission text file 0001213900-23-016044.txt   15112596

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cyto-20220630.xsd EX-101.SCH 240138
4 XBRL CALCULATION FILE cyto-20220630_cal.xml EX-101.CAL 40622
5 XBRL DEFINITION FILE cyto-20220630_def.xml EX-101.DEF 566991
6 XBRL LABEL FILE cyto-20220630_lab.xml EX-101.LAB 1161247
7 XBRL PRESENTATION FILE cyto-20220630_pre.xml EX-101.PRE 604096
155 EXTRACTED XBRL INSTANCE DOCUMENT ea174488-f1a2_altamira_htm.xml XML 2632180
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000 41 (0) 41 729 71 94
Altamira Therapeutics Ltd. (Filer) CIK: 0001601936 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: F-1/A | Act: 33 | File No.: 333-269823 | Film No.: 23692144
SIC: 2834 Pharmaceutical Preparations